GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sequana Medical NV (XBRU:SEQUA) » Definitions » Total Liabilities

Sequana Medical NV (XBRU:SEQUA) Total Liabilities : €28.74 Mil (As of Jun. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Sequana Medical NV Total Liabilities?

Sequana Medical NV's Total Liabilities for the quarter that ended in Jun. 2023 was €28.74 Mil.

Sequana Medical NV's quarterly Total Liabilities increased from Jun. 2022 (€17.71 Mil) to Dec. 2022 (€28.18 Mil) and increased from Dec. 2022 (€28.18 Mil) to Jun. 2023 (€28.74 Mil).

Sequana Medical NV's annual Total Liabilities increased from Dec. 2020 (€14.10 Mil) to Dec. 2021 (€15.49 Mil) and increased from Dec. 2021 (€15.49 Mil) to Dec. 2022 (€28.18 Mil).


Sequana Medical NV Total Liabilities Historical Data

The historical data trend for Sequana Medical NV's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sequana Medical NV Total Liabilities Chart

Sequana Medical NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Total Liabilities
Get a 7-Day Free Trial Premium Member Only 22.10 8.42 14.10 15.49 28.18

Sequana Medical NV Semi-Annual Data
Dec15 Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.79 15.49 17.71 28.18 28.74

Sequana Medical NV Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Sequana Medical NV's Total Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=15.148+(12.802+1.5265566588596E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0.228)
=28.18

Total Liabilities=Total Assets (A: Dec. 2022 )-Total Equity (A: Dec. 2022 )
=26.025--2.153
=28.18

Sequana Medical NV's Total Liabilities for the quarter that ended in Jun. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=13.87+(14.482+-2.2204460492503E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0.385)
=28.74

Total Liabilities=Total Assets (Q: Jun. 2023 )-Total Equity (Q: Jun. 2023 )
=25.127--3.61
=28.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sequana Medical NV Total Liabilities Related Terms

Thank you for viewing the detailed overview of Sequana Medical NV's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Sequana Medical NV (XBRU:SEQUA) Business Description

Traded in Other Exchanges
Address
Kortrijksesteenweg 1112 ,bus 102, Sint-Denijs-Westrem, Ghent, BEL, 9051
Sequana Medical NV is a commercial-stage medical device company focused on the development of treatment solutions for the management of fluid overload in liver disease, malignant ascites, and heart failure. The company's products include an alfa pump, which provides a treatment solution for the long-term management of liver refractory ascites and malignant ascites with safety, efficacy, and quality of life benefits demonstrated in multiple clinical studies and over 750 implants. The company's geographical segments include Switzerland, Germany, the United Kingdom, and the Rest of the world, out of which Germany accounts for the majority of the revenue.

Sequana Medical NV (XBRU:SEQUA) Headlines

No Headlines